DJIA 17,260.73 191.86 1.12%
NASDAQ 4,610.29 62.46 1.37%
S&P 500 2,002.64 29.90 1.52%
market minute promo


3.16 0.08 (2.44%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

VVUS $3.16 2.44%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $3.07
Previous Close $3.08
Daily Range $3.05 - $3.18
52-Week Range $2.92 - $9.80
Market Cap $327.1M
P/E Ratio -4.34
Dividend (Yield) $0.00 (0.0%)
Volume 1,405,310
Average Daily Volume 1,983,133
Current FY EPS -$0.78





VIVUS, Inc. (VVUS) Description

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products. Website:

News & Commentary Rss Feed

This Growing Concern Accounts For Nearly 500,000 Cancer Cases Each Year

A recent World Health Organization study shows that this growing problem is responsible for nearly a half-million cancer diagnoses each year.

Vivus Tries To Lead Obesity Space With Insurance Coverage

Low-Cost Contrave Fuels Anti-Obesity Drugs Recovery From Thanksgiving

Why Should Investors Expect Physicians To Treat Obesity With Pharmacotherapy?

Contrave Sales Continue To Impress

Others Overlooked VIVUS (VVUS), Should You Buy It Now? - Tale of the Tape

Will Diabetes Drugs Enter The Anti-Obesity Space?

Could This Company Follow in Dendreon's Footsteps?

Dendreon's fall from grace wasn't pretty, and another once highly regarded biotech may eventually follow suit.

Why Orexigen Therapeutics, Inc. Stock Rocketed 43% Higher in November

Orexigen Therapeutics is the best biotech stock in November after its earnings report highlights progress with its Contrave program overseas.

Belviq Approaches 10,000 Ads Aired

See More VVUS News...

VVUS's Top Competitors

VVUS $3.16 (2.44%)
Current stock: VVUS
JNJ $103.47 (0.69%)
Current stock: JNJ
NVS $91.72 (0.08%)
Current stock: NVS
RHHBY $35.86 (-1.24%)
Current stock: RHHBY